If anything good resulted from the global pandemic, it’s been the industry’s quick adoption of decentralized clinical trial (DCT) strategies in order to ensure clinical trial continuity.
While DCTs offer much promise for the future of clinical trials, in order for them to become a permanent part of the clinical research culture, we still need to consider how this new approach impacts clinical trial sites and what we can do to help ease the transition. Additionally, slapping a ‘DCT’ label on a clinical trial does not necessarily mean it overcomes the many barriers to trial enrollment nor that it opens the recruitment floodgates.
Recently, Florence Healthcare’s Chief Clinical Trial Officer Catherine Gregor participated in a roundtable discussion with Aperio’s Senior Director Corporate Strategy to talk about decentralized clinical trials and what sponsors and CROs can do to be truly more site- and patient-centric.
Check out part 1 of the conversation, where Kniola and Gregor discuss how sponsors can better meet the needs of sites in the Decentralized Clinical Trial journey.